LGND News and Press, Ligand Pharmaceuticals Incorporated From 12/13/21

COLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that the company, in collaboration w...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Benchmark is maintaining its buy rating on shares of Ligand Pharmaceuticals (LGND +6.7%) after the company beat on Q3 2021 earnings. The firm is also maintaining its $ price target (~19% upside). Analyst Robert Wasserman writes that revenue growth in the quarter was buoyed by sales of Captiso...

Image source: The Motley Fool. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Q3 2021 Earnings Call Nov 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earni...

Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Simon Latimer - Head of IR John Higgins - CEO Matthew Korenberg - CFO Matt Foehr - COO Conference Call Participants Lawrence Solow - CJS Securities Matt Hewitt - Cra...

Ligand Pharmaceuticals (NASDAQ:LGND): Q3 Non-GAAP EPS of $1.58 beats by $0.54; GAAP EPS of $0.80 beats by $0.50. Revenue of $68.84M (+64.5% Y/Y) beats by $12.58M. Ligand is reaffirming 2021 financial guidance. Ligand expects full-year 2021 total revenues to be between $265 million and $275 mi...

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2021 and provided an operating forecast and program updates. Ligand management wil...

Strategic Decision Based Upon Recent Business Success and Plans to Support Continued Growth and Investments in OmniAb’s Drug Discovery Platform Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eas...

BEPro is a novel prodrug technology to enhance oral delivery of active nucleotides Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive ...